Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

On the basis of strong preclinical rationale, we sought to confirm recommended phase II dose (RP2D) for olaparib, a PARP inhibitor, combined with the AKT inhibitor capivasertib and assess molecular markers of response and resistance. We performed a safety lead-in followed by expansion in endometrial...

Full description

Bibliographic Details

Published in:	Clinical cancer research Vol. 27; no. 23; p. 6354
Main Authors:	Westin, Shannon N, Labrie, Marilyne, Litton, Jennifer K, Blucher, Aurora, Fang, Yong, Vellano, Christopher P, Marszalek, Joseph R, Feng, Ningping, Ma, XiaoYan, Creason, Allison, Fellman, Bryan, Yuan, Ying, Lee, Sanghoon, Kim, Tae-Beom, Liu, Jinsong, Chelariu-Raicu, Anca, Chen, Tsun Hsuan, Kabil, Nashwa, Soliman, Pamela T, Frumovitz, Michael, Schmeler, Katheleen M, Jazaeri, Amir, Lu, Karen H, Murthy, Rashmi, Meyer, Larissa A, Sun, Charlotte C, Sood, Anil K, Coleman, Robert L, Mills, Gordon B
Format:	Journal Article
Language:	English
Published:	United States 01.12.2021
Subjects:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Female Humans Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology Phthalazines Piperazines Pyrimidines Pyrroles Triple Negative Breast Neoplasms - drug therapy
ISSN:	1557-3265, 1557-3265
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!